ASTELLAS PHARMA INC. 
By
Tokyo, February 28, 2014 - Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka, hereinafter called "the Company") announced that at the meeting of the Board of Directors held today, it resolved to conduct a stock split and partially amend the Articles of Incorporation as follows:
Particulars
1. Purpose of Stock Split
The purpose of the stock split is to expand the Company's investor base and enhance the liquidity of its stock by reducing the price per unit of shares to provide investors with more affordable purchase opportunities.
2. Outline of Stock Split
(1) Method of stock split
The stock split shall have a record date of Monday, March 31, 2014 and shall involve the splitting of common stock owned by shareholders entered or recorded in the last register of shareholders as of the record date at a ratio of 5 for 1.
(2) Increase in number of shares by stock split
Total number of issued shares before stock split: 456,964,635 shares Increase in number of shares by stock split: 1,827,858,540 shares Total number of issued shares after stock split: 2,284,823,175 shares Total number of authorized shares after stock split: 9,000,000,000 shares
(3) Schedule of stock split
Public notice date of record date: Friday, March 14, 2014
Record date: Monday, March 31, 2014
Effective date: Tuesday, April 1, 2014
3. Partial Amendment to the Articles of Incorporation along with Stock Split
(1) Reason for amendment
Along with the stock split, the Company shall amend Article 6 (Total number of authorized shares) of the Articles of Incorporation of the Company, effective April 1, 2014, in accordance with the provisions of Article 184, Paragraph 2 of the Companies Act.
(2) Details of amendment
The Articles of Incorporation will be amended as follows: (The amended parts are underlined.)
Present Articles of Incorporation | Amended Articles of Incorporation |
Article 6. (Total number of authorized shares) The total number of shares that the Company may issue shall be two billion shares (2,000,000,000). | Article 6. (Total number of authorized shares) The total number of shares that the Company may issue shall be nine billion shares (9,000,000,000). |
4. Adjustment to Exercise Price of Stock Options (Stock Acquisition Rights)
Along with the stock split, the exercise price of the 2nd stock acquisition rights issued by the Company shall be adjusted as follows, effective April 1, 2014.
Exercise price of stock acquisition rights
Exercise price per share before adjustment | Exercise price per share after adjustment | |
The 2nd stock acquisition rights | ¥3,690 | ¥738 |
5. Others
(1) Changes in capital
The stock split will not result in changes in capital. (2) Dividends
As the effective date of the stock split is April 1, 2014, the year-end dividend for the fiscal year ending
March 31, 2014, will be paid on the basis of the number of shares before the stock split.
The dividend forecast for the fiscal year ending March 31, 2014, has not been changed (year-end dividend of ¥70 per share).
######
For inquiries or additional information
Astellas Pharma Inc. Corporate Communications
TEL: +81-3-3244-3201, FAX:+81-3-5201-7473
http://www.astellas.com/en
2
|
distributed by
|
